유선 양성 질환과 조기 유방암 : 시장 인사이트, 역학, 시장 예측(2034년)

Benign Breast Disease and Early Breast Cancer - Market Insights, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,795,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,693,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,590,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 35,386,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주요 7개국의 유선 양성 질환 및 조기 유방암 시장 규모는 조사 기간(2020-2034년) 동안 상당한 CAGR로 성장할 것으로 예상됩니다.

미국에서는 생검을 통해 확진되는 양성유방질환이 침윤성 유방암보다 4배 더 많으며, 연간 100만 명의 여성이 이 질환으로 고통받고 있습니다. 조기암 및 양성유방질환은 진행성 질환보다 적응증이 넓고 대상 인구가 많기 때문에 시장을 선점할 수 있는 잠재력이 있으며, 2023년 미국이 주요 7개국 중 가장 큰 시장 규모를 보일 것으로 예상됩니다. 시장 점유율은 독일이 가장 높고, 스페인이 가장 낮을 것으로 예상됩니다.

COVID-19는 유방암 검진, 조기 진단 및 모든 암 치료에 극적인 영향을 미쳤습니다. 예를 들어 검진 프로그램이 중단되었고, 일부 전신 치료는 보류되었으며, 재건 수술이나 위험 감소 수술은 시행되지 않았습니다.

모든 양성 유방 질환의 아형 중 섬유선종은 임상적으로 진단되는 가장 흔한 아형으로, 미국에서는 전체 아형의 약 70%를 차지합니다.

양성유방질환은 임상검사, 정기적인 영상 진단, 환자의 자가검진 또는 유방통으로 발견되는 병변의 스펙트럼으로, 적절한 영상 진단과 적응증에 맞는 샘플링을 통해 양성 진단을 확인한 후, 치료는 증상 완화와 환자 교육에 초점을 맞추고 추가적인 외과적 시술를 하지 않습니다. 양성 병변은 젊은 나이에 많이 발생하며, 양성 유방 질환은 10대 후반부터 증가하기 시작하여 40-50대에 최고조에 달할 전망입니다.

조기 유방암은 암이 유방이나 같은 쪽 겨드랑이 림프절을 넘어 전이되지 않았다는 의미입니다. 즉, 암이 신체의 다른 부위로 퍼지지 않았다는 뜻입니다. 유방암의 병기 분류 체계는 유방암을 여러 단계로 분류합니다. 조기 유방암에는 0기, i기, II기가 있습니다.

양성 유방 질환의 진단에 사용되는 검사 및 시술은 조기 유방암의 진단에 사용되는 것과 동일한 경우가 많습니다. 진단의 목적은 발견된 성장이나 다른 변화가 양성인지 확인하고, 그 상태가 암 위험 증가와 관련이 있는지 여부를 판단하는 것입니다. 진단에 사용되는 검사로는 유방의 임상 검사, 엑스레이, 초음파, MRI, 유방촬영술과 같은 영상 진단이 있습니다. 또한 유선 양성 질환이나 조기 유방암의 진단을 위해 생검을 고려하기도 합니다.

주요 7개국에서 2023년 유방암 및 조기 유방암의 총 시장 규모는 약 88억 달러에 달할 것으로 예상됩니다. 이 시장은 예측 기간(2024-2034년) 동안 확대될 것으로 예상됩니다.

미국이 주요 7개국 전체 시장 규모에서 가장 큰 점유율(약 51%)을 차지하고 있으며, 그 다음으로 EU 4개국과 영국이 약 42% 시장 점유율을 차지하고 있습니다.

미국 시장 규모는 환자 수 증가와 질환에 대한 인식 개선으로 CAGR 2.9%로 증가할 것으로 예상됩니다.

주요 7개국에서 유선 양성 질환과 조기 유방암 시장에 대해 조사했으며, 시장의 개요와 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측 및 의료 미충족 요구 등을 제공하고 있습니다.

목차

제1장 주요 인사이트

제2장 리포트 서론

제3장 개요

제4장 역학과 시장 예측의 조사 방법

제5장 양성 유선 질환과 조기 유방암 시장 개요(주요 7개국)

제6장 질환의 배경과 개요

• 서론
  • 분류
  • 징후와 증상
  • 원인
  • 리스크 평가
• 진단
  • 양성 유방 질환의 진단
  • 조기 유방암의 진단

제7장 양성 유방 질환과 조기 유방암 치료

• 양성 유방 질환 치료
• 조기 유방암 치료

제8장 가이드라인

제9장 양성 유선 질환과 조기 유방암 역학과 환자 인구

• 주요 조사 결과
• 가정과 근거
• 주요 7개국에서 유방암 발증 총수
• 주요 7개국에서 양성 유선 질환 및 조기 유방암 발생 건수
• 미국
• EU4개국과 영국
• 일본

제10장 양성 유방 질환과 조기 유방암 환자 동향

제11장 양성 유선 질환과 조기 유방암의 출시가 끝난 기기

제12장 양성 유선 질환과 조기 유방암 : 주요 7개국 분석

• 주요 조사 결과
• 시장 전망
• 주요 7개국에서 양성 유선 질환 및 조기 유방암 전체 시장 규모
• 주요 7개국에서 양성 유선 질환 및 조기 유방암 수술 옵션별 시장 규모
• 미국 시장 규모
• EU4개국과 영국 시장 규모
• 일본 시장 규모

제13장 양성 유선 질환과 조기 유방암 미충족 요구

제14장 SWOT 분석

제15장 KOL의 견해

제16장 시장 접근과 상환의 개요

• 미국
• EU4개국과 영국
• 일본

제17장 부록

제18장 DelveInsight의 서비스 내용

제19장 면책사항

제20장 DelveInsight 소개

KSA

영문 목차

영문목차

Key Highlights:

• The Benign Breast Disease and Early Breast Cancer market size in the 7MM is aniticipated to grow with a significant CAGR during the study period (2020-2034)
• In the United States, biopsy-confirmed benign breast disease diagnoses are four times more common than invasive breast cancers, affecting ~1 million women annually. There is lucrative potential to seize the marketplace of early-stage cancerous and benign breast disease because it is a broader indication and represents a greater population than an advanced disease.
• In 2023, the market size of benign breast disease and early breast cancer was highest in the US among the 7MM. Amongst EU4 and the UK, Germany accounted for the highest market share in 2023, and Spain captured the least market share.
• The COVID-19 pandemic has dramatically impacted breast cancer screening, early diagnosis, and all cancer treatments: for example, screening programs were halted, some systemic therapies were withheld, and reconstructive and risk-reducing surgeries were not performed.
• Unlike breast cancer, data and guidelines for investigating and managing benign breast disease are limited. To date, there are no guidelines available for imaging surveillance after mastectomy.
• Among all the benign breast disease subtypes, fibroadenoma is the most common clinically diagnosed subtype accounting for approximately 70% of all subtypes in the US.
• Even with trends toward increasing mastectomy rates, the current rates of lumpectomy (breast-conserving surgery (~60% nationwide) remain above 50% at American Cancer Society and American College of Surgeons Commission on Cancer (ACS/CoC) centers in the United States. Data also suggests that the European centers have established higher benchmarks for breast-conserving surgeries, expecting that at least 70% of women with early breast cancer undergo breast-conserving surgery. The National Accreditation Center for Breast Cancer Standards in the US concurs with the European Society of Breast Cancer Specialists (EUSOMA-multi-institutional European database) recommendations, as it establishes that breast-conserving surgery should be offered or performed in early-stage breast cancer (stages 0, I, II) to at least 50% of cases.
• Novel technologies, patients' awareness of breast cancer early detection methods as a standard of healthcare, and compliance to screening help detect breast cancer at very early stages.
• Minimally invasive techniques like cryoablation and laser ablation have gained attention in the past few years as an alternative to surgical excision, potentially reducing complications, improving tencosmesis, and reducing hospital stays.

DelveInsight's "Benign Breast Disease and Early Breast Cancer Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Benign Breast Disease and Early Breast Cancer, historical and forecasted epidemiology as well as the Benign Breast Disease and Early Breast Cancer therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The benign breast disease and early breast cancer market report provides current treatment practices, market share of individual interventions, and current and forecasted 7MM benign breast disease and early breast cancer market size from 2020 to 2034. The report also covers current benign breast disease and early breast cancer treatment practices and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Study Period 2020 to 2034

Forecast Period 2024-2034

Geographies Covered * The US, EU4 (Germany, France, Italy, and Spain) and UK, Japan

Benign Breast Disease and Early Breast Cancer Market * Total Market Size

• Market Size by Therapies
• Market Size by Class

Benign Breast Disease and Early Breast Cancer Companies Merck & Co., Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi, and others.

Benign Breast Disease and Early Breast Cancer Epidemiology Segmentation * Total incident cases of breast cancer in the 7MM

• Total Incident Cases of Benign Breast Disease and Early Breast Cancer
• Benign Breast Disease Cases by Clinical Type in the 7MM
• Early Breast Cancer Cases by Age in the 7MM
• Total benign breast disease and early breast cancer patients seeking treatment in the 7MM

Benign Breast Disease and Early Breast Cancer Treatment Market

Benign Breast Disease and Early Breast Cancer Overview

Benign breast disease is a spectrum of lesions that are frequently discovered on clinical examination, routine imaging, by the patient on self-examination, or due to mastalgia, and after appropriate imaging and indicated sampling confirm a benign diagnosis, treatment is directed to symptomatic relief and the patient education without additional surgical management. Benign lesions are more common at younger ages, with benign breast disease beginning to rise in the second decade and peaking between the ages of 40 and 50.

Early breast cancer means cancer has not spread beyond the breast or the lymph nodes in the armpit on the same side of the body. So, cancer has not spread to any other part of the body. The number staging system divides breast cancers into different stages. Early breast cancer includes Stage 0, Stage I, and Stage II.

Benign Breast Disease and Early Breast Cancer Diagnosis

The tests and procedures used to diagnose a benign breast condition are often the same as those used to diagnose early breast cancer. The goals of diagnosis are to ensure that the growth or other change detected is benign and determine whether the condition is associated with any increase in cancer risk. Clinical breast examination, and diagnostic imaging, including X-ray, ultrasound, MRI, and mammography, are some diagnostic tests used for diagnosis. Furthermore, a biopsy is also considered to diagnose benign breast disease and early breast cancer.

Benign Breast Disease and Early Breast Cancer Treatment

Most types of benign breast disease do not require treatment. The healthcare provider may recommend treatment if one has atypical hyperplasia or a different kind of benign breast disease that increases the future risk of breast cancer. Similarly, treating early breast cancer aims to eliminate cancer and keep it from returning, for which a treatment plan is made based on medical and personal choices. Treatment includes surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy, and targeted therapy.

Benign Breast Disease and Early Breast Cancer Epidemiology

As the market is derived using a patient-based model, the Benign Breast Disease and Early Breast Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of breast cancer, total incident cases of benign breast disease and early breast cancer, benign breast disease cases by clinical type, early breast cancer cases by age, and total benign breast disease and early breast cancer patients seeking treatment in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• The total incident cases of benign breast disease and early breast cancer in the 7MM comprised approximately 2.9 million and 544,200 cases respectively, in 2023 and are projected to increase during the forecasted period.
• The United States contributed to the largest incident population of benign breast disease and early breast cancer, acquiring ~49% of the 7MM, followed by EU4 and the UK, and Japan in 2023.
• The total number of incident cases of benign breast disease and early breast cancer in the United States was around 1.4 million and 243,500 cases, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest number of benign breast disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2023.
• Most benign tumors of the breast do not require treatment, because such tumors or lesions are not life threatening and it takes years to progress into cancer. After diagnosing a benign breast lump, a physician may simply suggest a "wait-and-watch" approach to monitor the mass for changes. Surgical removal may be recommended if a noncancerous mass grows large enough to cause discomfort or press on a vital structure, such as a nerve or blood vessel. Data in the secondary domain suggests that nearly 30%-50% of BBD cases receive any kind of treatment at some time in their life.

Benign Breast Disease and Early Breast Cancer Interventions

Benign Breast Disease and Early Breast Cancer Marketed Drugs

ECHOPULSE: Theraclion

ECHOPULSE, developed by Theraclion, is the first robotic and non-invasive solution for echotherapy treatment (High-Intensity Focused Ultrasound HIFU) of breast fibroadenoma. The therapeutic ultrasound is combined with a standard ultrasound beam to control the accuracy of the treatment. It can be operated by a single person in a nonsurgical environment and leaves no scars, and maintains the thyroid function and the integrity of the breast tissue.

ProSense: IceCure Medical

ProSense by IceCure Medical is a liquid-nitrogen-based cryoablation system that allows for minimally invasive breast cancer treatment for the treatment of T1 invasive breast cancer and/or patients unsuitable for a surgical alternative for breast cancer. IceCure's unique ultra-slim probe freezes targeted tissue using advanced cryotherapy technology within minutes.

Guided by CT or ultrasound, the probe is inserted into the tumor, and liquid nitrogen generates sub-zero temperatures to turn the tumor into an ice ball. A freeze-thaw-freeze cycle destroys the targeted tissue immediately, leaving adjacent healthy tissue undamaged. The necrotic debris is eventually absorbed by the body.

Benign Breast Disease and Early Breast Cancer Market Outlook

The current market has been segmented into different commonly used therapeutic interventions based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall intervention patterns. Surgery including lumpectomy, mastectomy, minimally invasive procedures, and surgical excision in benign breast disease, are the major interventions covered in the forecast model.

The total market size of Benign Breast Disease and Early Breast Cancer in the 7MM is approximately USD 8,800 million in 2023 and is projected to increase during the forecast period (2024-2034).

The US accounted for the maximum share of the total market size in the 7MM, i.e., ~51%, followed by EU4 and the UK, capturing around 42% market share.

The market size in the United States will increase at a CAGR of 2.9% due to an increase in the patient pool and awareness of the disease.

Among EU4 countries, Germany accounts for the maximum market size in 2023, while Spain occupies the bottom of the ladder.

KOL Views

To keep up with current market trends, we take KOL's, and SME's opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on benign breast disease and early breast cancer evolving treatment landscape, patient reliance on conventional surgical options, patient acceptability of other surgical alternatives, and uptake of newer devices along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists, and Professors, MD from Department of Oncoplastic Breast Surgery Croydon University Hospital, London, UK, MD from Department of General Surgery Pullman Regional Hospital and Clinic Network, MD from Duke University, Durham, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, University of Edinburg, Cancer Research UK Barts Centre in London, New York Presbyterian Hospital/Weill Cornell Medical College, etc., were contacted. Their opinion helps understand and validate current treatment patterns, benign breast disease, and early breast cancer market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Benign Breast Disease and Early Breast Cancer Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Benign Breast Disease and Early Breast Cancer Market Access and Reimbursement

Breast cancer has the highest treatment cost of any cancer, accounting for 14% of all cancer treatment costs. Medicare pays for certain preventive healthcare services and screening tests to help find cancer. Part B also covers diagnostic mammograms more frequently than once a year when medically necessary. Patients pay 20% of the Medicare-approved amount for diagnostic mammograms; the Part B deductible applies. However, in Europe, inappropriate reimbursement and funding rules and regulations act as disincentives to best breast cancer care or, at worst, hinder best care. Reimbursement policies have rarely evolved with advances in breast cancer care such as outpatient (ambulatory) care rather than inpatient admission, use of oral or SC anticancer drugs rather than day-hospital IV administration, oncoplastic surgery techniques to minimize mastectomy rates, breast reconstructive surgery, and risk-reducing surgery for BRCA mutation carriers, or use of hypofractionated breast radiation therapy. Although each European country, region, and center must understand how their reimbursement policies may hinder best care and find solutions, the problems are similar throughout Europe, and some solutions can be broadly applied.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Benign Breast Disease and Early Breast Cancer Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of benign breast disease and early breast cancer, explaining its causes, signs and symptoms, classification, and currently available interventions.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression with treatment guidelines.
• Additionally, an all-inclusive account of both the current interventions, along with the elaborative profiles of newer surgical options will have an impact on the current treatment landscape.
• A detailed review of the benign breast disease and early breast cancer market, historical and forecasted market size, market share by surgery options, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and surgery preference that help shape and drive the 7MM benign breast disease and early breast cancer market.

Benign Breast Disease and Early Breast Cancer Report Insights

• Benign Breast Disease and Early Breast Cancer Patient Population
• Benign Breast Disease and Early Breast Cancer Therapeutic Approaches
• Benign Breast Disease and Early Breast Cancer Market Size and Trends
• Existing and future Market Opportunity

Benign Breast Disease and Early Breast Cancer Report Key Strengths

• 11 years Forecast
• 7MM Coverage
• Benign Breast Disease and Early Breast Cancer Epidemiology Segmentation
• Key Cross Competition

Benign Breast Disease and Early Breast Cancer Report Assessment

• Current Benign Breast Disease and Early Breast Cancer Treatment Practices
• Benign Breast Disease and Early Breast Cancer Unmet Needs
• Benign Breast Disease and Early Breast Cancer Market Attractiveness
• Qualitative Analysis (SWOT)
• Benign Breast Disease and Early Breast Cancer Market Drivers
• Benign Breast Disease and Early Breast Cancer Marke Barriers

Key Questions Answered In The Benign Breast Disease and Early Breast Cancer Market Report

Benign Breast Disease and Early Breast Cancer Market Insights

• What were the total market size of benign breast disease and early breast cancer, the market size by surgery options, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for different types of surgeries?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What will be the market share of different surgery options among lumpectomy, mastectomy, minimally invasive surgery, and others?
• Why the patient share of mastectomy is increasing in the US?
• Will minimally invasive surgical procedures be the preferred choice for benign breast disease?

Benign Breast Disease and Early Breast Cancer Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of benign breast disease and early breast cancer? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to benign breast disease and early breast cancer?
• What is the historical and forecasted benign breast disease and early breast cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What factors affect the increase in the diagnosis of benign breast disease and early breast cancer cases?
• What percentage of people with early breast cancer and benign breast disease seek treatment?

Benign Breast Disease and Early Breast Cancer Current Treatment Scenario

• What are the current options for the treatment of benign breast disease and early breast cancer? What are the current guidelines for treating benign breast disease and early breast cancer in the US and Europe?
• What are the recent novel devices, procedures, and technologies developed to overcome the limitation of existing therapies?
• What is the cost burden of approved interventions on the patient?
• Patient acceptability in terms of preferred surgical options as per real-world scenarios?
• What are the country-specific accessibility issues of diagnostic and surgical procedures?
• What are the 7MM historical and forecasted benign breast disease and early breast cancer market?

Reasons to Buy Benign Breast Disease and Early Breast Cancer Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the benign breast disease and early breast cancer market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Highlights of Access and Reimbursement policies of approved interventions, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Epidemiology and Market Forecast Methodology

5 Benign Breast Disease and Early Breast Cancer Market Overview at a Glance in the 7MM

• 5.1 Market Share (%) Distribution by Surgery Options in 2023
• 5.2 Market Share (%) Distribution by Surgery Options in 2034

6 Disease Background and Overview

• 6.1 Introduction
  • 6.1.1 Classification
  • 6.1.2 Signs and symptoms
  • 6.1.3 Causes
  • 6.1.4 Risk assessment
• 6.2 Diagnosis
  • 6.2.1 Diagnosis of benign breast disease
  • 6.2.2 Diagnosis of early breast cancer

7 Benign Breast Disease and Early Breast Cancer Treatment

• 7.1 Treatment of Benign Breast Disease
• 7.2 Treatment of Early Breast Cancer

8 Guidelines

• 8.1 Summary of breast cancer screening recommendations for women at average risk in the United States
• 8.2 Clinical Management Guidelines for Obstetrician-Gynecologists by the American College of Obstetricians and Gynecologists (2016)
• 8.3 Clinical Practice Guidelines from the French College of Gynecologists and Obstetricians (2016)
• 8.4 Breast Cancer Screening Guidelines by the US Preventive Services Task Force (USPSTF) (2016)
• 8.5 American Cancer Society Recommendations for the Early Detection of Breast Cancer (2022)
• 8.6 Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk by the ACR and Society of Breast Imaging (2021)
• 8.7 Early and Locally Advanced Breast Cancer: Diagnosis and Management by National Institute for Health and Care Excellence (NICE) (2018)
• 8.8 European Commission Initiative on Breast Cancer (ECIBC) Guidelines for Screening Ages (2022)
• 8.9 The Japanese Breast Cancer Society Clinical Practice Guidelines for Surgical Treatment of Breast Cancer (2018)
• 8.10 Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up (2019)

9 Benign Breast Disease and Early Breast Cancer Epidemiology and Patient Population

• 9.1 Key Findings
• 9.2 Assumption and Rationale
• 9.3 Total Incident Cases of Breast Cancer in the 7MM
• 9.4 Total Incident Cases of Benign Breast Disease and Early Breast Cancer in the 7MM
• 9.5 United States
  • 9.5.1 Total Benign Breast Disease and Early Breast Cancer Incident Cases in the US
  • 9.5.2 Benign Breast Disease Cases by Clinical Type in the US
  • 9.5.3 Early Breast Cancer Cases by Age in the US
  • 9.5.4 Total Benign Breast Disease and Early Breast Cancer Patients Seeking Treatment in the US
• 9.6 EU4 and the UK
  • 9.6.1 Total Incident Cases of Benign Breast Disease and Early Breast Cancer in EU4 and the UK
  • 9.6.2 Benign breast disease cases by clinical type in EU4 and the UK
  • 9.6.3 Early Breast Cancer Cases by Age in EU4 and the UK
  • 9.6.4 Total Benign Breast Disease and Early Breast Cancer Patients Seeking Treatment in EU4 and the UK
• 9.7 Japan
  • 9.7.1 Total Incident Cases of Benign Breast Disease and Early Breast Cancer in Japan
  • 9.7.2 Benign Breast Disease Cases by Clinical Type in Japan
  • 9.7.3 Early Breast Cancer Cases by Age in Japan
  • 9.7.4 Total Benign Breast Disease and Early Breast Cancer Patients Seeking Treatment in Japan

10 Benign Breast Disease and Early Breast Cancer Patient Journey

11 Benign Breast Disease and Early Breast Cancer Marketed Devices

• 11.1 Key Competitors

12 Benign Breast Disease and Early Breast Cancer: 7MM Analysis

• 12.1 Key Findings
• 12.2 Market Outlook
• 12.3 Total Market Size of Benign Breast Disease and Early Breast Cancer in the 7MM
• 12.4 Market Size of Benign Breast Disease and Early Breast Cancer by Surgery Options in the 7MM
• 12.5 United States Market Size
  • 12.5.1 Total Market Size of Benign Breast Disease and Early Breast Cancer in the US
  • 12.5.2 Market Size of Benign Breast Disease and Early Breast Cancer by Surgery Options in the US
• 12.6 EU4 and the UK Market Size
  • 12.6.1 Total Market Size of Benign Breast Disease and Early Breast Cancer in EU4 and the UK
  • 12.6.2 Market Size of Benign Breast Disease and Early Breast Cancer by Surgery Options in EU4 and the UK
• 12.7 Japan Market Size
  • 12.7.1 Total Market Size of Benign Breast Disease and Early Breast Cancer in Japan
  • 12.7.2 Market Size of Benign Breast Disease and Early Breast Cancer by Surgery Options in Japan

13 Benign Breast Disease and Early Breast Cancer Unmet Needs

14 SWOT Analysis

15 KOL Views

16 Market Access and Reimbursement Overview

• 16.1 The United States
  • 16.1.1 Centre for Medicare and Medicaid Services (CMS)
• 16.2 EU4 and the UK
  • 16.2.1 Germany
  • 16.2.2 France
  • 16.2.3 Italy
  • 16.2.4 Spain
  • 16.2.5 The United Kingdom
• 16.3 Japan
  • 16.3.1 MHLW
• 16.4 Market access and reimbursement of Benign Breast Disease and Early Breast Cancer
  • 16.4.1 Echopulse
  • 16.4.2 ProSense
  • 16.4.3 Axxent Electronic Brachytherapy (eBx) System

17 Appendix

• 17.1 Bibliography
• 17.2 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

관련자료